Erica D. Warlick

4.5k citations

109 papers · 2.4k indexed · 1 hit paper · h-index 25

Hematology top 0.5%
Oncology top 5%
Immunology top 5%
Public Health, Environmental and Occupational Health top 5%
Molecular Biology

Co-authors: Daniel J. Weisdorf Jeffrey S. Miller Claudio G. Brunstein Todd E. DeFor Michael R. Verneris Daniel A. Vallera Bruce R. Blazar Adina Cioc
Topics: Acute Myeloid Leukemia Research (65 papers)Hematopoietic Stem Cell Transplantation (60 papers)Acute Lymphoblastic Leukemia research (34 papers)
Cited by: Hematology Immunology Oncology
Journals: Journal of Clinical Oncology Blood Cancer
Partner nations: United States Spain France

In The Last Decade

Erica D. Warlick

105 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

2017 400 citations Marcelo C. Pasquini, Steven M. Devine et al. profile →

Peers

Countries citing papers authored by Erica D. Warlick

Since Specialization

Citations

This map shows the geographic impact of Erica D. Warlick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica D. Warlick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica D. Warlick more than expected).

Fields of papers citing papers by Erica D. Warlick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica D. Warlick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica D. Warlick. The network helps show where Erica D. Warlick may publish in the future.

Co-authorship network of co-authors of Erica D. Warlick

This figure shows the co-authorship network connecting the top 25 collaborators of Erica D. Warlick. A scholar is included among the top collaborators of Erica D. Warlick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica D. Warlick. Erica D. Warlick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia 2025 ·Blood Advances ·Farhad Ravandi,Sravanti Rangaraju,Hagop M. Kantarjian,Guillermo Garcia‐Manero,Musa Yılmaz,(unknown),Terence Hall,John D. Grabenstein,(unknown),(unknown),William C. Zamboni,Erica D. Warlick,Michael J. Kelly,David A. Roth,Gabriel Ghiaur	1
2	A randomized, phase II trial of adjuvant immunotherapy with durable TKI-free survival in patients with chronic phase CML 2021 ·Leukemia Research ·Jonathan Webster,Tara M. Robinson,Amanda L. Blackford,Erica D. Warlick,Anna Ferguson,Ivan Borrello,Marianna Zahurak,Richard J. Jones,B. Douglas Smith	4
3	First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings 2021 ·Blood Advances ·Margaret L. MacMillan,Keli L. Hippen,David H. McKenna,Diane Kadidlo,Darin Sumstad,Todd E. DeFor,Claudio G. Brunstein,Shernan G. Holtan,Jeffrey S. Miller,Erica D. Warlick,Daniel J. Weisdorf,John E. Wagner,Bruce R. Blazar	54
4	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant 2021 ·Bone Marrow Transplantation ·(unknown),Daniel J. Weisdorf,John E. Wagner,Bruce R. Blazar,Margaret L. MacMillan,Todd E. DeFor,Aleksandr Lazaryan,Najla El Jurdi,Shernan G. Holtan,Claudio G. Brunstein,Brian C. Betts,(unknown),Veronika Bachanová,Erica D. Warlick,Armin Rashidi,Mukta Arora	4
5	GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts 2020 ·Blood ·Erica D. Warlick,Daniel J. Weisdorf,Daniel A. Vallera,(unknown),Dixie Lewis,(unknown),(unknown),Martin Felices,Jeffrey S. Miller	29
6	Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function 2020 ·JCI Insight ·Dhifaf Sarhan,(unknown),(unknown),(unknown),Michael R. Verneris,Bartosz Grzywacz,Erica D. Warlick,Bruce R. Blazar,Jeffrey S. Miller	40
7	Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis 2020 ·Biology of Blood and Marrow Transplantation ·Armin Rashidi,Mohamad Aghaie Meybodi,Wenhao Cao,Haitao Chu,Erica D. Warlick,Steven M. Devine,Marcelo C. Pasquini,Daniel J. Weisdorf,Mehdi Hamadani	9
8	Prognostic factors for clinical outcomes of patients with central nervous system leukemia 2020 ·Hematology/Oncology and Stem Cell Therapy ·(unknown),Qing Cao,Zohar Sachs,Angela R. Smith,Sarah Williams,Khalid Amin,Veronika Bachanová,Erica D. Warlick,Claudio G. Brunstein,Daniel J. Weisdorf,Nelli Bejanyan	3
9	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up 2018 ·Biology of Blood and Marrow Transplantation ·Erica D. Warlick,Todd E. DeFor,Nelli Bejanyan,Shernan G. Holtan,Margaret L. MacMillan,Bruce R. Blazar,Kathryn E. Dusenbery,Mukta Arora,Veronika Bachanová,Sarah Cooley,Aleksandr Lazaryan,Philip B. McGlave,Jeffrey S. Miller,Armin Rashidi,Arne Slungaard,Gregory M. Vercellotti,Celalettin Üstün,(unknown),Daniel J. Weisdorf	8
10	Absence of early HHV‐6 reactivation after cord blood allograft predicts powerful graft‐versus‐tumor effect 2018 ·American Journal of Hematology ·Armin Rashidi,Maryam Ebadi,(unknown),Qing Cao,Ryan Shanley,Julie Curtsinger,Nelli Bejanyan,Erica D. Warlick,Jaime S. Green,Claudio G. Brunstein,Jeffrey S. Miller,Daniel J. Weisdorf	2
11	Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics 2018 ·Haematologica ·(unknown),(unknown),Qing Cao,Nelli Bejanyan,Armin Rashidi,Aleksandr Lazaryan,Patrick Arndt,(unknown),Veronika Bachanová,Erica D. Warlick,Margaret L. MacMillan,Mukta Arora,Jeffrey S. Miller,Claudio G. Brunstein,Daniel J. Weisdorf,Celalettin Üstün	20
12	Multiple transmissions of chromosomally integrated human herpesvirus‐6 in one family 2017 ·Transplant Infectious Disease ·Armin Rashidi,(unknown),Joshua A. Hill,Erica D. Warlick,Daniel J. Weisdorf	0
13	History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease‐negative first complete remission 2017 ·American Journal of Hematology ·Armin Rashidi,Michael A. Linden,Todd E. DeFor,Erica D. Warlick,Nelli Bejanyan,Sophia Yohe,Daniel J. Weisdorf,Celalettin Üstün	15
14	MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes 2016 ·Bone Marrow Transplantation ·(unknown),Todd E. DeFor,(unknown),Michelle Dolan,Claudio G. Brunstein,Nelli Bejanyan,(unknown),Erica D. Warlick	3
15	Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies 2016 ·Leukemia Research ·Kelly J. Norsworthy,Eunpi Cho,Jyoti Arora,Jeanne Kowalski,Hua-Ling Tsai,Erica D. Warlick,Margaret M. Showel,Keith W. Pratz,Lesley Sutherland,Steven D. Gore,Anna Ferguson,(unknown),(unknown),Igor Espinoza‐Delgado,Richard J. Jones,William Matsui,B. Douglas Smith	11
16	Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes 2015 ·Cancer Epidemiology ·Jenny N. Poynter,Michaela Richardson,Cindy K. Blair,Michelle A. Roesler,Betsy Hirsch,Phuong Nguyen,Adina Cioc,Erica D. Warlick,James R. Cerhan,Julie A. Ross	64
17	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia 2013 ·Biology of Blood and Marrow Transplantation ·Régis Peffault de Latour,Claudio G. Brunstein,Raphaël Porcher,Patrice Chevallier,Marie Robin,Erica D. Warlick,Aliénor Xhaard,Celalettin Üstün,Jérôme Larghero,Nathalie Dhédin,Mohamad Mohty,Gèrard Socié,Daniel J. Weisdorf	61
18	Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions 2010 ·Current Opinion in Oncology ·Erica D. Warlick	1
19	Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes 2008 ·Leukemia Research ·Erica D. Warlick,Paul V. O’Donnell,Michael J. Borowitz,(unknown),(unknown),Elizabeth Garrett‐Mayer,Ivan Borrello,Robert A. Brodsky,Ephraim J. Fuchs,Carol Ann Huff,Leo Luznik,William Matsui,Richard F. Ambinder,Richard J. Jones,B. Douglas Smith	13
20	Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches 2007 ·Current Cancer Drug Targets ·Erica D. Warlick,Benjamin D. Smith	24

About Erica D. Warlick

Erica D. Warlick is a scholar working on Hematology, Transplantation and Public Health, Environmental and Occupational Health, having authored 109 papers that have together received 2.4k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (65 papers), Hematopoietic Stem Cell Transplantation (60 papers) and Acute Lymphoblastic Leukemia research (34 papers). The work is most often cited by research in Hematology (1.6k citations), Immunology (812 citations) and Oncology (858 citations). Erica D. Warlick has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Daniel J. Weisdorf, Jeffrey S. Miller, Claudio G. Brunstein, Todd E. DeFor, Michael R. Verneris, Daniel A. Vallera, Bruce R. Blazar, Adina Cioc, Julie A. Ross and Michelle Dolan. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact